120 related articles for article (PubMed ID: 38837876)
1. Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long-term endpoint: The non-Gaussian case.
Garcia Barrado L; Burzykowski T
Pharm Stat; 2024 Jun; ():. PubMed ID: 38837876
[TBL] [Abstract][Full Text] [Related]
2. Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long-term clinical endpoint.
Garcia Barrado L; Burzykowski T; Legrand C; Buyse M
Pharm Stat; 2022 Jan; 21(1):209-219. PubMed ID: 34505395
[TBL] [Abstract][Full Text] [Related]
3. Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint.
Fougeray R; Vidot L; Ratta M; Teng Z; Skanji D; Saint-Hilary G
Pharm Stat; 2024 Jul; ():. PubMed ID: 38956450
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis incorporating short- and long-term binary endpoints.
Niewczas J; Kunz CU; König F
Biom J; 2019 May; 61(3):665-687. PubMed ID: 30694566
[TBL] [Abstract][Full Text] [Related]
5. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
Jörgens S; Wassmer G; König F; Posch M
Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
[TBL] [Abstract][Full Text] [Related]
6. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Group sequential designs for stepped-wedge cluster randomised trials.
Grayling MJ; Wason JM; Mander AP
Clin Trials; 2017 Oct; 14(5):507-517. PubMed ID: 28653550
[TBL] [Abstract][Full Text] [Related]
9. Evaluating futility of a binary clinical endpoint using early read-outs.
Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
[TBL] [Abstract][Full Text] [Related]
10. Interim monitoring of clinical trials based on long-term binary endpoints.
Marschner IC; Becker SL
Stat Med; 2001 Jan; 20(2):177-92. PubMed ID: 11169596
[TBL] [Abstract][Full Text] [Related]
11. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
13. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
14. Sample size adjustment designs with time-to-event outcomes: A caution.
Freidlin B; Korn EL
Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
[TBL] [Abstract][Full Text] [Related]
15. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
Li X; Herrmann C; Rauch G
BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
[TBL] [Abstract][Full Text] [Related]
16. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
Van Lancker K; Vandebosch A; Vansteelandt S
Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
[TBL] [Abstract][Full Text] [Related]
17. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
Roig MB; Melis GG; Posch M; Koenig F
Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
[TBL] [Abstract][Full Text] [Related]
18. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
[TBL] [Abstract][Full Text] [Related]
19. Choosing Interim Sample Sizes in Group Sequential Designs.
Tarima S; Flournoy N
Stud Health Technol Inform; 2021 May; 278():11-16. PubMed ID: 34042870
[TBL] [Abstract][Full Text] [Related]
20. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
